- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05024019
Nimotuzumab Combined With Radiotherapy in High-risk Patients With HNSCC Not Suitable for Cisplatin After Surgery
August 20, 2021 updated by: Eye & ENT Hospital of Fudan University
A Multicenter Clinical Study of Nimotuzumab Combined With Concurrent Radiotherapy Versus Radiotherapy Alone in High-risk Patients With Head and Neck Squamous Cell Carcinoma Not Suitable for Cisplatin After Surgery
This study is a prospective, open label, multicenter, randomized controlled clinical trial.
The main purpose of the study is to evaluate the efficacy and safety of nimotuzumab combined with concurrent radiotherapy versus radiotherapy alone in high-risk patients with HNSCC not suitable for cisplatin after surgery.
The subjects were randomly divided into study group (nimotuzumab combined with concurrent radiotherapy) and control group (radiotherapy alone) by 1∶1 stratified random method.
Study Overview
Status
Not yet recruiting
Conditions
Intervention / Treatment
Detailed Description
This study is a prospective, open label, multicenter, randomized controlled clinical trial.
The main purpose of the study is to evaluate the efficacy and safety of nimotuzumab combined with concurrent radiotherapy versus radiotherapy alone in high-risk patients with HNSCC not suitable for cisplatin after surgery.
The subjects were randomly divided into study group and control group by 1∶1 stratified random method.
The study group received nimotuzumab (200mg, weekly, for 6 weeks) combined with concurrent radiotherapy, while the control group received radiotherapy alone.
The main endpoint is 2 year disease free survival (DFS) rate.
Study Type
Interventional
Enrollment (Anticipated)
95
Phase
- Phase 2
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Contact
- Name: Lei Tao
- Phone Number: 64377134
- Email: doctortaolei@163.com
Study Contact Backup
- Name: Yang Guo
- Email: guoyangls@126.com
Study Locations
-
-
-
Hangzhou, China
- The First Affiliated Hospital of Zhejiang University
-
Contact:
- Xiaoli Sun
-
Hangzhou, China
- Zhejiang Cancer Hospital
-
Contact:
- Xiaozhong Chen
-
Nanjing, China
- Jiangsu Province Hospital
-
Contact:
- Yuandong Cao
-
Ningbo, China
- Ningbo Medical Center Lihuili Hospital
-
Contact:
- Miaozhen Lu
-
Shanghai, China
- Huadong Hospital affiliated to Fudan University
-
Contact:
- Xiangpeng Zheng
-
Shanghai, China
- Shanghai General Hospital/First People's Hospital Affiliated with Shanghai Jiao Tong University
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
16 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Age ≥18 years;
- Histology or imaging diagnosed as head and neck (oropharyngeal cancer, hypopharyngeal cancer, laryngeal cancer) squamous cell carcinoma; oropharyngeal cancer should be p16 negative (p16 positive defined as p16 ≥ 70%);
- The radical surgery has been completed and patients were suffered from any postoperative risk factors as follows: (1) extranodal extension (ENE); (2) pT3-4; pN2-3; (3) Nerve invasion (PNI) or vascular invasion (LVI); (4) Lymph node metastasis in zone IV or zone V (oral/oropharyngeal cancer); (5) Proximal margin (< 5mm);
- Immunohistochemical detection indicated the EGFR expressions were positive;
- The patients were not suitable for cisplatin chemotherapy: (1) Age>65 years; (2) ECOG PS score>2; (3) Renal dysfunction (creatinine clearance <60ml/min); (4) Severe tinnitus or hearing loss (need hearing aids or hearing tests show 25 decibels threshold or above at two consecutive frequencies); (5) peripheral neuropathy severer than 1 level ; (6) Unable to accept venous hydration, such as cardiac dysfunction or other comorbidities (judged by the investigator); (7) The patient refuses cisplatin chemotherapy;
- Imaging examination did not suggest distant metastasis;
- Expected survival time ≥ 6 months;
- The following criteria must be met (No transfusion of blood or blood products within 14 days prior to screening): Hb≥90g /L; ANC≥1.0×10*9 /L; PLT≥80×10*9 /L; white blood cell count ≥ 4×10*9 /L; Biochemical examination need to meet the following criteria: serum total bilirubin (TBIL) ≤1.5 ULN; aminotransferase (AST)/alanine aminotransferase (ALT) ≤2.5 ULN.
- For females of reproductive age, the patients must have a negative pregnancy test (serum or urine) within 14 days prior to enrollment and be willing to use a reliable method of contraception during the trial. Male subjects should use a reliable method of contraception from the beginning of treatment until 120 days after the last medication;
- The subjects voluntarily joined the study and signed the informed consent, with good compliance and follow-up.
Exclusion Criteria:
- The patients received chemotherapies, PD-1 inhibitors, monoclonal antibody against EGFR, EGFR-TKI, anti-angiogenic drugs within 4 weeks before enrollment;
- The patients participated in other interventional clinical trials within 30 days before screening;
- There was a history of other malignant tumors within the past 5 years, except for cured cervical carcinoma in situ, non-melanoma skin cancer, localized prostate cancer, ductal carcinoma in situ;
- Poorly controlled concurrent diseases (such as heart failure, diabetes, hypertension, thyroid disease, mental illness, etc.);
- Known to be infected with HIV virus or active viral hepatitis or tuberculosis;
- There is major surgery within 30 days before taking the trial drug for the first time or there is planned surgery;
- Allergic to the drugs or their components used in this program;
- Pregnancy (confirmed by blood or urine HCG test) or breastfeeding women, or subjects of childbearing age who are unwilling or unable to take effective contraceptive measures (applicable to both male and female subjects) until at least 6 months after the last trial treatment;
- Patients who are not suitable to participate in this research according to the evaluations of researchers;
- Those who are unwilling to participate in this study or unable to sign the informed consent form.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Study group
The study group received nimotuzumab (200mg, weekly, for 6 weeks) combined with concurrent radiotherapy.
|
The study group received nimotuzumab (200mg, weekly, for 6 weeks) in combination with radiotherapy.
|
No Intervention: Control group
The control group received radiotherapy alone.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Disease free survival (DFS)
Time Frame: 2 year
|
2 year
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Overall survival (OS)
Time Frame: 2 year
|
2 year
|
|
Local area recurrence free survival (LRRFS)
Time Frame: 2 year
|
2 year
|
|
Distant metastasis free survival (DMFS)
Time Frame: 2 year
|
2 year
|
|
Quality of life assessed by EORTC QLQ-H&N35
Time Frame: 2 year
|
Quality of life assessed by EORTC QLQ-H&N35 [EORTC QLQ-H&N35 is a specific quality of life assessment scale based on EORTC QLQ-C 30, with 35 items.
All of the scales and single-item measures range from 0 to 100.
A high score represents a higher response level.]
|
2 year
|
Incidence of treatment-emergent adverse events
Time Frame: 2 year
|
Including the incidence of treatment-emergent adverse events[Safety and Tolerability].
Adverse events should be reported and graded according to CTCAE version 5.0.
|
2 year
|
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
The change of tumor related markers
Time Frame: 2 year
|
The correlation of the value of EGFR, SCC-Ag, CEA and therapeutic effect [The changes of serum tumor markers (such as SCC-Ag and CEA were observed before and after treatment.
The baseline EGFR levels on the prognosis of patients should also be explored]
|
2 year
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Anticipated)
August 21, 2021
Primary Completion (Anticipated)
August 21, 2025
Study Completion (Anticipated)
August 21, 2025
Study Registration Dates
First Submitted
August 15, 2021
First Submitted That Met QC Criteria
August 20, 2021
First Posted (Actual)
August 27, 2021
Study Record Updates
Last Update Posted (Actual)
August 27, 2021
Last Update Submitted That Met QC Criteria
August 20, 2021
Last Verified
August 1, 2021
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- BPL-Nim-SCCHN-6
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Head and Neck Squamous Cell Carcinoma
-
Washington University School of MedicineMerck Sharp & Dohme LLCActive, not recruitingHead and Neck Cancer | Squamous Cell Carcinoma of the Head and Neck | Cancer of Head and Neck | Carcinoma, Squamous Cell of Head and Neck | Neoplasms, Head and Neck | Squamous Cell Carcinoma, Head and NeckUnited States
-
Chase Heaton, MDIncyte Corporation; OncoSec Medical IncorporatedTerminatedRecurrent Head and Neck Squamous Cell Carcinoma | Metastatic Head and Neck Squamous Cell Carcinoma | Unresectable Head and Neck Squamous Cell CarcinomaUnited States
-
Wake Forest University Health SciencesNational Cancer Institute (NCI)RecruitingRecurrent Head and Neck Squamous Cell Carcinoma | Advanced Head and Neck Squamous Cell Carcinoma | Metastatic Head-and-neck Squamous-cell Carcinoma | Locally Advanced Head and Neck Squamous Cell Carcinoma | Stage III Cutaneous Squamous Cell Carcinoma of the Head and Neck | Stage IV Cutaneous...United States
-
Washington University School of MedicineActive, not recruitingSquamous Cell Carcinoma of the Head and Neck | Squamous Cell Carcinoma, Head and NeckUnited States
-
Yonsei UniversityCompletedHead Neck Cancer Squamous Cell Recurrent | Head Neck Cancer Squamous Cell MetastaticKorea, Republic of
-
Xiang LuRecruitingHead and Neck Squamous Cell Carcinomas | Resectable Head and Neck Squamous-cell CarcinomaChina
-
Medical College of WisconsinRecruitingResectable Head and Neck Squamous Cell CarcinomaUnited States
-
Bristol-Myers SquibbActive, not recruitingSquamous Cell Carcinoma of the Head and Neck; Head and Neck Cancer; Head and Neck Carcinoma; Cancer of the Head and NeckFrance
-
Wake Forest University Health SciencesNational Cancer Institute (NCI)RecruitingHead and Neck Squamous Cell Carcinoma | Recurrent Head and Neck Squamous Cell Carcinoma | Metastatic Head-and-neck Squamous-cell CarcinomaUnited States
-
Eben RosenthalNational Cancer Institute (NCI)CompletedHead and Neck Cancer | Head and Neck Squamous Cell Carcinoma | Squamous Cell Carcinoma of the Head and Neck (SCCHN)United States
Clinical Trials on Nimotuzumab
-
Cancer Institute and Hospital, Chinese Academy...UnknownGastric Cancer | Concurrent ChemoradiotherapyChina
-
Peking UniversityBiotech Pharmaceutical Co., Ltd.Unknown
-
Peking Union Medical College HospitalNot yet recruiting
-
Peking UniversityUnknownEsophageal Squamous Cell CancerChina
-
Oncoscience AGHeinrich-Heine University, Duesseldorf; University of Kiel; Johann Wolfgang Goethe... and other collaboratorsCompleted
-
University of SaskatchewanRecruitingColorectal Cancer | Lung CancerCanada
-
Oncoscience AGHeinrich-Heine University, Duesseldorf; University of Wuerzburg; Children's Medical... and other collaboratorsCompleted
-
YM BioSciencesCIMYM BioSciencesTerminatedMetastatic Non-Small Cell Lung CancerUnited States, Korea, Republic of, Canada, Cuba, Pakistan
-
Health Science Center of Xi'an Jiaotong UniversityRecruiting
-
University of SaskatchewanWestern Economic Diversification CanadaRecruiting